Modulating bladder neuro-inflammation: RDP58, a novel anti-inflammatory peptide, decreases inflammation and nerve growth factor production in experimental cystitis
- PMID: 15643278
- DOI: 10.1097/01.ju.0000143192.68223.f7
Modulating bladder neuro-inflammation: RDP58, a novel anti-inflammatory peptide, decreases inflammation and nerve growth factor production in experimental cystitis
Abstract
Purpose: In interstitial cystitis (IC) inflammation induces and perpetuates neurotrophic changes in the bladder, resulting in the symptoms of frequency, urgency and pain. RDP58 (NH2-arg-norleucine (nle)-nle-arg-nle-nle-nle-gly-tyr-CONH2) (Sangstat Corp., Fremont, California) is a novel synthetic peptide that inhibits early signal transduction pathways for the expression of inflammatory cytokines. In this study we evaluated the effects of intravesical RDP58 on an established model of cystitis.
Materials and methods: Mice were catheterized and equal volumes of Escherichia coli lipopolysaccharide (LPS) or saline were instilled into the bladder. After 45 minutes the bladders were drained and distilled water or RDP58 (1 mg/ml) was instilled for 30 minutes. At 24 hours later the bladders were excised and cultured for analysis of tumor necrosis factor-alpha (TNF-alpha), substance P (SP) and nerve growth factor (NGF) production, as quantified by enzyme-linked immunosorbent assay.
Results: LPS caused severe inflammation in mouse bladders compared with controls. Exposure to LPS increased the levels of TNF-alpha, SP and NGF production compared with controls (each p <0.05). In LPS exposed mice RDP58 significantly decreased inflammatory parameters by 82% 24 hours after treatment (p <0.05). Within 4 hours RDP58 abolished TNF-alpha production and at 24 hours TNF-alpha remained undetectable. RDP58 also significantly decreased SP and NGF production in LPS exposed bladders by more than 40% and 85%, respectively (each p <0.05).
Conclusions: Inflammatory models of cystitis result in increased levels of TNF-alpha, SP and NGF production in the bladder, paralleling the hypothesized neuro-inflammatory etiology of IC. RDP58 decreases inflammation and neurotrophic factors in vivo and it may potentially treat bladder disorders with an inflammatory component, such as IC.
Comment in
-
A potential modality for interstitial cystitis: intravesical use of anti-inflammatory peptide RDP58.J Urol. 2005 Feb;173(2):340. doi: 10.1097/01.ju.0000151249.65348.ca. J Urol. 2005. PMID: 15643170 No abstract available.
-
Re: Modulating bladder neuro-inflammation: RDP58, a novel anti-inflammatory peptide, decreases inflammation and nerve growth factor production in experimental cystitis.J Urol. 2005 Aug;174(2):790; author reply 790-2. J Urol. 2005. PMID: 16006984 No abstract available.
Similar articles
-
Re: Modulating bladder neuro-inflammation: RDP58, a novel anti-inflammatory peptide, decreases inflammation and nerve growth factor production in experimental cystitis.J Urol. 2005 Aug;174(2):790; author reply 790-2. J Urol. 2005. PMID: 16006984 No abstract available.
-
RDP58, a novel immunomodulatory peptide with anti-inflammatory effects. A pharmacological study in trinitrobenzene sulphonic acid colitis and Crohn disease.Scand J Gastroenterol. 2003 May;38(5):526-32. Scand J Gastroenterol. 2003. PMID: 12795464 Clinical Trial.
-
Intravesical nanocrystalline silver decreases experimental bladder inflammation.J Urol. 2008 Apr;179(4):1598-602. doi: 10.1016/j.juro.2007.11.037. Epub 2008 Mar 4. J Urol. 2008. PMID: 18295255
-
Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target.Neurourol Urodyn. 2011 Sep;30(7):1227-41. doi: 10.1002/nau.21022. Epub 2011 Apr 21. Neurourol Urodyn. 2011. PMID: 21520250 Review.
-
Rational design and development of RDP58.Curr Pharm Des. 2002;8(24):2217-29. doi: 10.2174/1381612023393170. Curr Pharm Des. 2002. PMID: 12369864 Review.
Cited by
-
Transgenic Mice Expressing MCP-1 by the Urothelium Demonstrate Bladder Hypersensitivity, Pelvic Pain and Voiding Dysfunction: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network Animal Model Study.PLoS One. 2016 Sep 29;11(9):e0163829. doi: 10.1371/journal.pone.0163829. eCollection 2016. PLoS One. 2016. PMID: 27684718 Free PMC article.
-
Establishment of a Novel Autoimmune Experimental Model of Bladder Pain Syndrome/Interstitial Cystitis in C57BL/6 Mice.Inflammation. 2017 Jun;40(3):861-870. doi: 10.1007/s10753-017-0531-7. Inflammation. 2017. PMID: 28233078
-
New Frontiers or the Treatment of Interstitial Cystitis/Bladder Pain Syndrome - Focused on Stem Cells, Platelet-Rich Plasma, and Low-Energy Shock Wave.Int Neurourol J. 2020 Sep;24(3):211-221. doi: 10.5213/inj.2040104.052. Epub 2020 Sep 30. Int Neurourol J. 2020. PMID: 33017892 Free PMC article.
-
Tryptase activation of immortalized human urothelial cell mitogen-activated protein kinase.PLoS One. 2013 Jul 29;8(7):e69948. doi: 10.1371/journal.pone.0069948. Print 2013. PLoS One. 2013. PMID: 23922867 Free PMC article.
-
TRPV4 Mediates Acute Bladder Responses to Bacterial Lipopolysaccharides.Front Immunol. 2020 May 6;11:799. doi: 10.3389/fimmu.2020.00799. eCollection 2020. Front Immunol. 2020. PMID: 32435246 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources